Ishita Patel, MD
Endocrinology, Diabetes & Metabolism · Round Rock, TXNPI 1295052462
Payments from drug & device makers
Across 365 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$1000
- AstraZeneca$887
- Novo Nordisk$852
- Lilly USA, LLC$833
- Amgen$810
- Sanofi-aventis U.S. LLC$537
- plus $3K from 34 others
What the payments were for
- Food & beverage$8,174100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 8 | $1,000 |
| AstraZeneca(2 entities) | 40 | $887 |
| Novo Nordisk | 55 | $852 |
| Lilly USA, LLC | 37 | $833 |
| Amgen(2 entities) | 39 | $810 |
| Sanofi-aventis U.S. LLC | 27 | $537 |
| Boehringer Ingelheim | 28 | $433 |
| Medtronic(2 entities) | 16 | $375 |
| BETA Bionics, Inc. | 6 | $294 |
| Corcept Therapeutics | 13 | $229 |
| Insulet Corporation | 11 | $201 |
| Xeris Pharmaceuticals, Inc. | 9 | $176 |
| AbbVie | 9 | $166 |
| Tandem Diabetes Care, Inc. | 5 | $147 |
| Abbott | 7 | $140 |
| Dexcom, Inc. | 5 | $96 |
| Cequr Corporation | 4 | $82 |
| Radius Health, Inc. | 3 | $77 |
| Recordati_rare_diseases_inc. | 3 | $68 |
| IBSA Pharma Inc. | 4 | $61 |
| Acella Pharmaceuticals, LLC | 3 | $61 |
| Shire North American Group Inc | 3 | $56 |
| Antares Pharma, Inc. | 3 | $56 |
| Novartis | 2 | $51 |
| Pfizer | 3 | $51 |
| Alvogen Inc | 2 | $50 |
| Bayer | 3 | $49 |
| Mannkind Corporation | 2 | $38 |
| Sequel Med Tech, LLC | 2 | $35 |
| Soleno Therapeutics, Inc. | 1 | $35 |
| Merck | 2 | $28 |
| Astellas Pharma US Inc | 1 | $26 |
| Johnson & Johnson | 2 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INJECTAFER$1,000
- iLet Bionic Pancreas$312
- FARXIGA$250
- TRULICITY$125
- Prolia$125
- MOUNJARO$125
- Wegovy$101
How this compares
$8,174 in reported general payments places this provider in the 60th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 196 | $222,685 |
| MounjaroTirzepatide | 180 | $222,304 |
| JardianceEmpagliflozin | 93 | $89,924 |
| FarxigaDapagliflozin Propanediol | 75 | $85,596 |
| TrulicityDulaglutide | 45 | $72,668 |
| ForteoTeriparatide | 13 | $60,328 |
| JanuviaSitagliptin Phosphate | 20 | $29,068 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $27,259 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $27,170 |
| TradjentaLinagliptin | 46 | $26,233 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $17,960 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $12,514 |
| SynthroidLevothyroxine Sodium | 107 | $9,768 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $9,094 |
| Novolog FlexpenInsulin Aspart | 12 | $6,590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo | $833 | $355,300238 claims |
| Novo NordiskOzempic | $852 | $222,685196 claims |
| Boehringer IngelheimJardiance, Tradjenta | $433 | $116,157139 claims |
| AstraZenecaFarxiga | $887 | $85,59675 claims |
| MerckJanuvia | $28 | $29,06820 claims |
| AbbVieSynthroid, Armour Thyroid | $166 | $11,887127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Round Rock
- Hien TranRound Rock$3.6M
- Kerem OzerRound Rock$2.3M
- Stephanie ShawRound Rock$936K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.